Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Resistance to proteasome inhibitors and other targeted therapies in myeloma
Craig T. Wallington‐Beddoe, Magdalena Sobieraj‐Teague, Bryone J. Kuss, et al.
British Journal of Haematology (2018) Vol. 182, Iss. 1, pp. 11-28
Open Access | Times Cited: 99

Showing 1-25 of 99 citing articles:

The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, et al.
Drug Resistance Updates (2019) Vol. 47, pp. 100646-100646
Closed Access | Times Cited: 112
Prognostic and predictive biomarker developments in multiple myeloma
Craig T. Wallington‐Beddoe, Rachel L. Mynott
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 93
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
Grazia R. Tundo, Diego Sbardella, Anna Maria Santoro, et al.
Pharmacology & Therapeutics (2020) Vol. 213, pp. 107579-107579
Open Access | Times Cited: 88
MIR145-3ppromotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targetingHDAC4
Hong-Kun Wu, Chang Liu, Qingyuan Yang, et al.
Autophagy (2019) Vol. 16, Iss. 4, pp. 683-697
Open Access | Times Cited: 81
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
Eric K. Rowinsky, Agne Paner, Jesús G. Berdeja, et al.
Investigational New Drugs (2020) Vol. 38, Iss. 5, pp. 1448-1453
Open Access | Times Cited: 80
Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma
Sinan Xiong, Wee Joo Chng, Jianbiao Zhou
Cellular and Molecular Life Sciences (2021) Vol. 78, Iss. 8, pp. 3883-3906
Open Access | Times Cited: 58
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Hui Ming, Bowen Li, Jingwen Jiang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 30
What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg
Teodora Alexa‐Stratulat, Milica Pešić, Ana Čipak Gašparović, et al.
Drug Resistance Updates (2019) Vol. 46, pp. 100643-100643
Closed Access | Times Cited: 67
Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease
David J. Sherman, Jing Li
Molecules (2020) Vol. 25, Iss. 3, pp. 671-671
Open Access | Times Cited: 64
MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines
Katharina Uhr, Wendy J. C. Prager‐van der Smissen, Anouk A. J. Heine, et al.
PLoS ONE (2019) Vol. 14, Iss. 5, pp. e0216400-e0216400
Open Access | Times Cited: 63
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action
Kitsada Wudhikarn, Beatriz Wills, Alexander M. Lesokhin
Best Practice & Research Clinical Haematology (2020) Vol. 33, Iss. 1, pp. 101143-101143
Open Access | Times Cited: 52
Regulation and Functions of the ER-Associated Nrf1 Transcription Factor
Gary Ruvkun, Nicolas J. Lehrbach
Cold Spring Harbor Perspectives in Biology (2022) Vol. 15, Iss. 1, pp. a041266-a041266
Open Access | Times Cited: 35
Multicolumn Nanoflow Liquid Chromatography with Accelerated Offline Gradient Generation for Robust and Sensitive Single-Cell Proteome Profiling
Xiaofeng Xie, Thy Truong, Siqi Huang, et al.
Analytical Chemistry (2024) Vol. 96, Iss. 26, pp. 10534-10542
Closed Access | Times Cited: 8
Curcumin in treatment of hematological cancers: Promises and challenges
Maliheh Entezari, Armita Tayari, Mahshid Deldar Abad Paskeh, et al.
Journal of Traditional and Complementary Medicine (2024) Vol. 14, Iss. 2, pp. 121-134
Open Access | Times Cited: 6
Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies
Francesco Malfona, Anna Maria Testi, Sabina Chiaretti, et al.
Blood and Lymphatic Cancer Targets and Therapy (2024) Vol. Volume 14, pp. 1-15
Open Access | Times Cited: 6
The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies
Taylor Harding, Linda B. Baughn, Shaji Kumar, et al.
Leukemia (2019) Vol. 33, Iss. 4, pp. 863-883
Closed Access | Times Cited: 52
Childhood, adolescent and young adult non‐Hodgkin lymphoma: current perspectives
Mitchell S. Cairo, Auke Beishuizen
British Journal of Haematology (2019) Vol. 185, Iss. 6, pp. 1021-1042
Open Access | Times Cited: 50
Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma
Ying Xie, Jing Liu, Hongmei Jiang, et al.
Oncogene (2019) Vol. 39, Iss. 4, pp. 922-934
Closed Access | Times Cited: 47
Treatment of relapsed/refractory paediatric aggressive B‐cell non‐Hodgkin lymphoma
Maria Luisa Moleti, Anna Maria Testi, Robin Foà
British Journal of Haematology (2020) Vol. 189, Iss. 5, pp. 826-843
Open Access | Times Cited: 44
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma
Hector H. Huang, Ian Ferguson, Alexis M. Thornton, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 43
Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
Dawn Swan, Mark E. Gurney, Janusz Krawczyk, et al.
HemaSphere (2020) Vol. 4, Iss. 2
Open Access | Times Cited: 42
Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations
Gayathri Ravi, Susan Bal, Laura Joiner, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 4, pp. 1300-1306
Open Access | Times Cited: 5
Mature B‐NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies
Grace Egan, Stan Goldman, Sarah Alexander
British Journal of Haematology (2019) Vol. 185, Iss. 6, pp. 1071-1085
Open Access | Times Cited: 36
Proteasome inhibition for the treatment of glioblastoma
Patrick Roth, Warren Mason, Paul G. Richardson, et al.
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 10, pp. 1133-1141
Open Access | Times Cited: 34
Overcoming proteasome inhibitor resistance in the immunotherapy era
Bonell Patiño-Escobar, Alexis Talbot, Arun P. Wiita
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 8, pp. 507-518
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top